ClinicalTrials.gg
CompletedNCT01713946EXIST-3Updated Nov 7, 2018Results posted

A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures

A Phase 3 interventional study of RAD001 and Placebo in Tuberous Sclerosis Complex-associated Refractory Seizures, sponsored by Novartis Pharmaceuticals. Completed at 104 sites in 25 countries. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-11-07.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
366
Allocation
Randomized
Ages
2 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Seizures by Novartis — none open to participants now, 1 under way, 1 of them phase 3. Seizures · Novartis.

Enrollment
Largest of 11
366 · median 94
Started
2013
the only one that year
Phase 3
5 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Seizures by Novartis, this one has the largest enrollment, is the only one that started in 2013, is one of 5 in phase 3, and was the 10th registered.

Seizures

766 studies on the registry are indexed under Seizures; 134 are open to participants now.

Browse Seizures studies →

Open to participants now

None of the 11 studies in Seizures by Novartis is open now. The open studies under Seizures, anywhere →

Who these studies take

Of the 92 Seizures studies recruiting now, 35 (38%) set no upper age limit and 44 (48%) stop at 75 or younger; 38 take children under 18; 18 take healthy volunteers.

This study: 2 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Seizures by Novartis as a file.
02

Study summary

This study evaluated the efficacy and safety of two trough-ranges of everolimus given as adjunctive therapy in patients with tuberous sclerosis complex (TSC) who had refractory partial-onset seizures.

The study consisted of 4 phases for each patient Baseline phase:[From Screening Week -8 (V1) to randomization visit at Week 0 (V2)], Core phase [from randomization at Week 0 (V2) to Week 18 (V11)], Extension phase [from Week 18 (V11) until 48 weeks after the last patient had completed the core phase] and Post Extension phase [from end of Extension phase to end of study].

03

Conditions studied

  • Tuberous Sclerosis Complex-associated Refractory Seizures

Keywords

  • TSC seizures
  • TSC epilepsy
  • mTOR inhibitor
  • RAD001
  • Everolimus
04

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Male or female between the ages of 2 and 65 years (except in Europe where minimum age will be 1).

      1. Clinically definite diagnosis of TSC per modified Gomez criteria 3. Diagnosis of partial-onset epilepsy according to the classification of the International League Against Epilepsy (1989) and revised in 2009.
      1. Uncontrolled partial-onset seizures; must meet the following:
      2. At least 16 reported quantifiable partial-onset seizures over the Baseline period with no continuous 21-day seizure-free period between Visit 1 (Screening Visit) and Visit 2 (Randomization visit), as per data captured in daily seizure diaries.
      3. Prior history of failure to control partial-onset seizures despite having been treated with two or more sequential regimens of single or combined antiepileptic drugs.
      4. Prior or concurrent use of vagal nerve stimulator (VNS) is allowed. If the patient is using VNS, device stimulator parameters must remain constant throughout the study.
      5. Prior epilepsy surgery is allowed if performed at least 12 months before study entry.

        1. Must be receiving one, two, or three AEDs at a stable dose for at least 4 weeks at the start of the 8-week prospective Baseline phase, remain on the same regimen throughout the Baseline phase, and intend to continue the same regimen throughout the 18-week double blind Core phase (rescue medications are permitted).
        1. If female of child bearing potential, documentation of negative pregnancy test at time of and must use highly effective during the study and for 8 weeks after stopping treatment 7. Sexually active males must use a condom during intercourse while taking study drug, and for 8 weeks after stopping study treatment 8. Hepatic, renal and blood laboratory values within the following range at screening :

      <!-- -->

      1. and ALT levels \< 2.5 x
      2. serum \<1.5 × ULN (this limit does not apply to patients with an elevated indirect bilirubin, if they have Gilbert's Syndrome),
      3. serum creatinine \< 1.5 x ULN
      4. ≥ 9 g/dL
      5. ≥ 80,000/mm3
      6. ≥ 1,000/mm3 9. Written informed consent. Subjects or their legal guardians must have the ability to comprehend the informed consent form and be willing to provide informed consent.

        1. Patient or caregiver must be able to reliably record seizures and keep a daily diary and recall adverse events.

Exclusion criteria

Exclusion Criteria:

    1. Patients with seizures secondary to metabolic, toxic, infectious or psychogenic disorder or drug abuse or current seizures related to an acute medical illness.

      1. Presence of only non-motor partial seizures (NOT APPLICABLE per Amendment 2) 3. Patients with TSC who have SEGA in need of immediate surgical intervention. 4. Patients under 2 years of age with untreated infantile spasms. 5. Within 52 weeks prior to study entry, an episode of status epilepticus as defined in the protocol.
      1. Patients with history of seizure clusters (where individual seizures cannot be accurately counted according to the judgment of the investigator) occurring within 26 weeks prior to study entry.
      1. Patients who require rescue medication during the baseline phase for more than 6 days 8. Patients with non-TSC related progressive encephalopathy. 9. Patients who weigh less than 12 kg. 10. Patients with coexisting within the 3 years prior to randomization, except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.
      1. Patients with any severe and/or uncontrolled medical conditions at randomization such as:
      2. Symptomatic congestive heart failure of Class III or IV, history of (LVEF) \< 50%, >460ms, congenital QT syndrome, unstable angina pectoris, myocardial infarction within 6 months of study entry, serious uncontrolled cardiac arrhythmia or any other cardiac disease.
      3. Significant symptomatic deterioration of lung function
      4. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, malabsorption syndrome or small bowel resection).
      5. liver disease such as cirrhosis, decompensated liver disease, and chronic hepatitis
      6. Uncontrolled diabetes as defined by fasting serum glucose > 1.5 × .
      7. Active skin, mucosa, ocular or GI disorders of Grade > 1.
      8. Active (acute or chronic) or uncontrolled severe infections.
      9. A known history of seropositivity or other active viral infections. 12. Patients with an active, bleeding diathesis. 13. Patient with uncontrolled hyperlipidemia: fasting serum cholesterol > 300 mg/dL OR >7.75 mmol/L AND fasting triglycerides > 2.5 x ULN.

        1. Patients who have had a major surgery or significant traumatic injury within 4 weeks of study entry.
        1. Patients with a prior history of organ transplant. 16. Patients receiving more than 3 antiepileptic drugs at any time in the baseline phase or at randomization or who change the dose of the AEDs during 4 weeks before screening or during the baseline period.
        1. Patients being treated with felbamate, unless treatment has been continuous for ≥ 1 year.
        1. Patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of study entry (including chemotherapy, radiation therapy, antibody based therapy, etc.).
        1. Prior treatment with any drug within the preceding 4 weeks prior to study entry.
        1. Patients receiving chronic, systemic treatment with or another agent at study entry. Topical or inhaled corticosteroids are allowed.
        1. Patients who have received prior treatment with a systemic mTOR inhibitor (sirolimus, temsirolimus, everolimus) within 24 months of study entry. Patients who have received prior treatment with a topical mTOR inhibitor (sirolimus, temsirolimus, everolimus) within 4 weeks of study entry.
        1. Patients with a known to everolimus or other rapamycin-analogues (sirolimus, temsirolimus) or to its .
        1. Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study 24. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
        1. Patients with a Score of 4 or 5 on the Suicidal Ideation item within 2 years of Screening, or any "yes" on the Suicidal Behavior item of the Columbia-Suicide Severity Rating Scale at Screening or Baseline , who upon follow up with a healthcare professional are found to be severely depressed or suicidal.
        1. Maintenance of a diet consisting of \<40 g of carbohydrate per day within 3 months of screening
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
366 participants (actual)

Study arms

  • Experimental
    Everolimus LT target of 3 - 7 ng/mL

    Participants received everolimus dispersible tablets for oral suspension with titration to a low trough (LT) range of 3 to 7 ng/mL plus 1 to 3 antiepileptic drugs.

    Drug: RAD001 · Drug: Antiepileptic drug (1 to 3 only) · Drug: open label RAD001 (only used for post-extension phase)

  • Experimental
    Everolimus HT target of 9 -15 ng/mL

    Participants received everolimus dispersible tablets for oral suspension with titration to a high trough (HT) range of 9 to 15 ng/mL plus 1 to 3 antiepileptic drugs.

    Drug: RAD001 · Drug: Antiepileptic drug (1 to 3 only) · Drug: open label RAD001 (only used for post-extension phase)

  • Placebo comparator
    Placebo

    Participants received placebo plus 1 to 3 antiepileptic drugs.

    Drug: Placebo · Drug: Antiepileptic drug (1 to 3 only) · Drug: open label RAD001 (only used for post-extension phase)

Interventions

  • DrugRAD001

    Everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.

    Also known as: everolimus

  • DrugPlacebo

    Placebo tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister packs and placed in boxes with color-coded labels, color 1 or color 2.

  • DrugAntiepileptic drug (1 to 3 only)

    no more than any 3 of the listed antiepileptic drugs could be taken with the study drug or placebo. List of allowed antiepileptic drugs were: valporic acid, carbamazepine, clobazam, N-desmethylclobazam, topiramate,TRI477, TRI476, clonazepam, zonisamide, phenobarbital, phenytoin

  • Drugopen label RAD001 (only used for post-extension phase)

    everolimus tablets for oral suspension (dispersible tablets) were packaged as 2 mg tablets in blister backs in boxes with open label design and were taken during the Post-Extension phase, where all the participants, including those who were previously on placebo, took the 2mg tablets.

    Also known as: open label everolimus

06

What researchers measure

Primary outcomes

  1. Core Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate

    Comparison of response rates in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. Response means at least a 50% reduction from baseline in partial-onset seizure frequency during the maintenance period of the core phase.

    Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

  2. Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure Frequency

    Comparison of median percent change from baseline in weekly seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase (SFcfb) = 100 × (SFB - SFM) ÷ SFB where: SFB is the average weekly seizure frequency in the Baseline phase SFM is the average weekly seizure frequency in the maintenance period of the Core phase A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.

    Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

Secondary outcomes

  1. Percentage of Seizure-free Patients During the Maintenance Period of the Core Phase

    Comparison of seizure freedom (100% reduction in seizure frequency) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Seizure free means a 100% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.

    Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

  2. Core Phase: Percentage of Patients With at Least a 25% Reduction in Seizure Frequency

    Comparison of percentage of patients with at least ≥ 25% reduction in seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. At least 25% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.

    Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

  3. Core Phase: Distribution of Reduction From Baseline in Seizure Frequency

    Comparison of percentage of patients in six categories of seizure reduction from baseline (≤ -25% (exacerbation); \> -25% to \< 25% (no change); ≥ 25% to \< 50%; ≥ 50% to \< 75%; ≥ 75% to \< 100%; 100% (seizure-freedom)) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase

    Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

  4. Core Phase: Changes From Baseline in Number of Seizure-free Days

    Comparison of seizure-free days relative to baseline in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase

    Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

  5. Core Phase: Probability That a Patient Remains On-treatment up to a Specified Time Point

    Comparison of time to treatment discontinuation in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during the core phase. Treatment duration is defined as the time from randomization until the date of permanent study treatment discontinuation (for any reason) at any time during the Core phase. The percentage event-free probability estimate is the estimated probability that a patient will remain on-treatment up to a specified time point (Week 6, 12, 18)

    Time frame: Week 6, Week 12, Week 18

  6. Core Phase: Change From Baseline in the QOLCE Overall Quality-of-life Score for Patients <11 Years

    Comparison of quality of life in the everolimus (from 3 age specific questionnaires) low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life Childhood Epilepsy (QOLCE) questionnaire, used for patients \< 11 years at baseline, was completed by the patient's parent or caregiver. It consists of 16 subscales (13 multi-item scales and 3 single item scales) and one overall quality-of-life score. Scores range from 0-100, with higher scores corresponding to improved QoL. The Overall Quality of Life Score is computed by adding each subscale score for each individual and then dividing by 16.

    Time frame: Baseline, Week 18

  7. Core Phase: Change From Baseline in the QOLIE-AD-48 Overall Quality-of-life Score for Patients >=11 to 18 Years

    Comparison of quality of life (from 3 age specific questionnaires) in the everolimus low-trough treatment arm (3-7 ng/mL), hightrough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life in Epilepsy Inventory for Adolescents-48 (QOLIE-AD-48) is a survey of health-related quality of life for adolescents 11 to 18 years of age with epilepsy. The QOLIE-AD-48 is completed by the patient. It contains 48 items which assess 8 subscales. Scores range from 0-100, with higher scores corresponding to improved QoL. The overall quality of life score is obtained by summing a linear combination of the 8 subscale scores, where each subscale is multiplied by a relative weight that is provided in the original publication.

    Time frame: Baseline, Week 18

  8. Core Phase: Change From Baseline in the QOLIE-31-P Overall Quality-of-life Score for Patients Aged >=18 Years

    Comparison of quality of life (from 3 age specific questionnaires) in the everolimus low-trough treatment arm (3-7 ng/mL), hightrough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life in Epilepsy Inventory-31-Problems (QOLIE-31-P) is a survey of health-related quality of life for adults with epilepsy. The QOLIE-31-P is completed by the patient. It contains 39 items, of which a total of 30 are used to make up 7 different subscales. Scores range from 0-100, with higher scores indicating a greater level of functioning and QoL. The overall quality of life score is obtained by summing a linear combination of the 7 subscale scores, where each subscale is multiplied by a relative weight that is obtained from the patient's answer to 7 items of this questionnaire.

    Time frame: Baseline, Week 18

  9. Core Phase: Change From Baseline in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score

    Comparison of adaptive functioning using the VABS-II composite score in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Vineland II assesses an individual's development of personal independence \& social responsibility. The questionnaire contains 433 items which assess 15 subdomains organized into the five domains of Communication, Daily Living Skills, Socialization, Motor Skills and Maladaptive Behavior. The overall Adaptive Behavior Composite (ABC) score is obtained by summing the standard scores of the first four domain scores for patients aged less than 7 years, or the first 3 domain scores for patients aged 7 or older (the Maladaptive Behavior domain is optional). The ABC standard score ranges from 20 to 160 with a mean of 100 and a standard deviation of 15. Higher scores correspond to improved adaptive level. Note that 2 questionnaires with ABC scores\<20 (data issues) were included in this analysis.

    Time frame: Baseline, 18 weeks

  10. Long Term Evaluation: Effect of Everolimus Over Time in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score

    Comparison of adaptive functioning using the VABS-II composite score in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Vineland II assesses an individual's development of personal independence \& social responsibility. The questionnaire contains 433 items which assess 15 subdomains organized into the five domains of Communication, Daily Living Skills, Socialization, Motor Skills and Maladaptive Behavior. The overall Adaptive Behavior Composite (ABC) score is obtained by summing the standard scores of the first four domain scores for patients aged less than 7 years, or the first 3 domain scores for patients aged 7 or older (the Maladaptive Behavior domain is optional). The ABC standard score ranges from 20 to 160 with a mean of 100 and a standard deviation of 15. Higher scores correspond to improved adaptive level. Note that 2 questionnaires with ABC scores\<20 (data issues) were included in this analysis.

    Time frame: Baseline, Weeks 18, 42, 66 and 90

  11. Core Phase: Change From Baseline in Wechsler Nonverbal Composite Score

    The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range.

    Time frame: Baseline, Week 18

  12. Long Term Evaluation: Effect of Everolimus Over Time in the Overall Wechsler Nonverbal Composite Score

    The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range

    Time frame: Baseline, Weeks 18, 42, 66 and 90

  13. Core Phase: Response Rate in Seizure Frequency by Time Normalized Minimum Concentration

    Comparison of response rate in seizure frequency for 5 categories of time-normalized minimum concentration (Cmin, TN) (\< 3 ng/mL; 3-7 ng/mL; \>7-\<9 ng/mL; 9-15 ng/mL; \>15 ng/mL). Response rate is the percentage of patients with ≥ 50% reduction from baseline in average weekly partial-onset seizure frequency during the maintenance period of the Core phase.

    Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

  14. Core Phase: Median Percentage Change From Baseline in Seizure Frequency by Time Normalized Minimum Concentration

    Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase is calculated as follow: (SFcfb) = 100 × (SFB - SFM) ÷ SFB where SFB is the average weekly seizure frequency in the Baseline phase and SFM is the average weekly seizure frequency in the maintenance period of the Core phase. A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.

    Time frame: Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)

  15. Long Term Evaluation: Relationship Between Seizure Frequency and Time-normalized Everolimus Concentration at Trough (Cmin,TN) - Repeated Measures Analysis

    A repeated measures analysis considering fixed 2-week intervals and including the level of exposure (time-normalized Cmin values), the time on-treatment and the seizure frequency at baseline quantified the estimated percentage change over 2 weeks in seizure frequency associated with a double exposure to everolimus, 15 days more on treatment and half the seizure frequency at baseline. A positive percentage change means a reduction in seizure frequency whereas a negative percentage change means an increase in seizure frequency.

    Time frame: During everolimus treatment from start of everolimus up to the end of the extension phase, an average of 1.7 year

  16. Core Phase: Impact of Everolimus on Anti-epileptic Drugs (AEDs) Concentrations

    Impact of everolimus on AED concentrations at trough. Pre-dose plasma samples to measure AED concentrations were measured at at Visits 1 (Screening), 2 (Baseline), 3, and 5. Effects of everolimus on the exposure of antiepileptic drugs was assessed by comparing the anti-epileptic drug concentrations at Visits 1 and 2 (AEDs alone) and at Visits 3 and 5 (AEDs plus everolimus).

    Time frame: Baseline, Weeks 1 & 3

  17. Long Term Evaluation: Percentage Change From Start of Everolimus in Seizure Frequency by Time Window

    Percentage change from start of everolimus in average weekly seizure frequency (SFcfe) = 100 × (SFe - SFtw) ÷ SFe where: SFe is the average weekly seizure frequency in the 8-week period before start of everolimus SFtw is the average weekly seizure frequency in a 12-week time window A positive percentage change from start of everolimus (SFcfe) means a reduction in seizure frequency whereas a negative percentage change from start of everolimus (SFcfe) means an increase in seizure frequency.

    Time frame: Baseline (8-week period before start of everolimus), Week 7 to 18, Week 19 to 30, and 12 weeks thereafter up to Week 102

  18. Seizure Free Rates by Time Window

    Percentage of seizure-free participants for each 12-week time window.

    Time frame: Weeks 18, 30, 42, 54, 66, 78, 90 & 102

  19. Core Phase: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes

    Comparison of suicidality using the C-SSRS in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire used for suicide assessment developed by multiple institutions, including Columbia University, with NIMH support. The scale is evidence-supported and is part of a national and international public health initiative involving the assessment of suicidality. There are different scoring systems depending on the population. The important elements to note are that the higher the scores on the individual items and the more "yes" items, the higher the suicide risk.

    Time frame: Baseline, Week 18

  20. Long Term Evaluation: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes

    The C-SSRS was completed at each visit. The table below presents the number of patients who reported at least one completed suicide, one suicide attempt, one preparatory action toward imminent suicidal behavior, one suicidal ideation and one self-injurious behavior without suicidal intent at any time point after starting everolimus.

    Time frame: During everolimus treatment from start of everolimus up to permanent discontinuation of everolimus, an average of 2.3 years

07

Results

Posted Nov 7, 2018

Participant flow

355 patients were planned to be enrolled and a total of 366 patients were randomized: 117 to the everolimus targeted low-trough arm (LT), 130 to the everolimus targeted high-trough (HT) arm, and 119 to treatment with placebo.

Participant flow — Overall Study
MilestoneEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Started117130119
Completed core phase110122114
Continued in ext. phase110119114
Completed ext. phase799281
Continued in post-ext. phase789081
Completed post-ext phase748575
Did not continue in ext phase030
Did not cont. in post-ext phase120
Completed748575
Not completed434544
Withdrew: Death022
Withdrew: Adverse event191413
Withdrew: Withdrawal by subject12128
Withdrew: Lack of efficacy8814
Withdrew: Protocol violation241
Withdrew: Lost to follow-up001
Withdrew: Administrative problems100
Withdrew: Did not continue in ext030
Withdrew: Did not continue in post-ext. phase120
Withdrew: Patients never switched to everolimus005

Outcome measures

PrimaryCore Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate

Comparison of response rates in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. Response means at least a 50% reduction from baseline in partial-onset seizure frequency during the maintenance period of the core phase.

Time frame:
Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Reported as:
Number · Percentage of responders
Core Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate
Percentage of respondersEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Core Phase: European Medicine Agency (EMA): Seizure Frequency Response Rate28.2 (20.3 to 37.3)40.0 (31.5 to 49.0)15.1 (9.2 to 22.8)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Bonferroni-Holm · p = 0.008 · Odds ratio (or): 2.21 · 95% CI 1.16 to 4.20
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Bonferroni-Holm · p = <0.001 · Odds ratio (or): 3.93 · 95% CI 2.10 to 7.32
PrimaryCore Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure Frequency

Comparison of median percent change from baseline in weekly seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase (SFcfb) = 100 × (SFB - SFM) ÷ SFB where: SFB is the average weekly seizure frequency in the Baseline phase SFM is the average weekly seizure frequency in the maintenance period of the Core phase A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.

Time frame:
Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Reported as:
Median · Percentage change from baseline
Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure Frequency
Percentage change from baselineEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Core Phase: Food & Drug Administration (FDA): Percentage Change From Baseline in Partial Onset-seizure Frequency29.29 (18.82 to 41.88)39.55 (35.03 to 48.74)14.86 (0.11 to 21.71)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Bonferroni-Holm · p = 0.003 · Median difference (final values): 15.96 · 95% CI 1.98 to 31.68
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Bonferroni-Holm · p = <0.001 · Odds ratio (or): 27.46 · 95% CI 16.36 to 43.36
SecondaryPercentage of Seizure-free Patients During the Maintenance Period of the Core Phase

Comparison of seizure freedom (100% reduction in seizure frequency) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. Seizure free means a 100% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.

Time frame:
Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Reported as:
Number · Percentage of seizure-free participants
Percentage of Seizure-free Patients During the Maintenance Period of the Core Phase
Percentage of seizure-free participantsEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Percentage of Seizure-free Patients During the Maintenance Period of the Core Phase5.1 (1.9 to 10.8)3.8 (1.3 to 8.7)0.8 (0.0 to 4.6)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Odds ratio (or): 6.55 · 95% CI 0.77 to 55.73
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Odds ratio (or): 4.99 · 95% CI 0.57 to 44.03
SecondaryCore Phase: Percentage of Patients With at Least a 25% Reduction in Seizure Frequency

Comparison of percentage of patients with at least ≥ 25% reduction in seizure frequency in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase. At least 25% reduction from baseline in partial-onset seizure frequency during maintenance period of the core phase.

Time frame:
Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Reported as:
Number · Percentage of participants
Core Phase: Percentage of Patients With at Least a 25% Reduction in Seizure Frequency
Percentage of participantsEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Core Phase: Percentage of Patients With at Least a 25% Reduction in Seizure Frequency52.1 (42.7 to 61.5)70.0 (61.3 to 77.7)37.8 (29.1 to 47.2)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Odds ratio (or): 1.77 · 95% CI 1.05 to 2.97
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Odds ratio (or): 3.82 · 95% CI 2.25 to 6.48
SecondaryCore Phase: Distribution of Reduction From Baseline in Seizure Frequency

Comparison of percentage of patients in six categories of seizure reduction from baseline (≤ -25% (exacerbation); \> -25% to \< 25% (no change); ≥ 25% to \< 50%; ≥ 50% to \< 75%; ≥ 75% to \< 100%; 100% (seizure-freedom)) in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase

Time frame:
Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Reported as:
Number · Percentage of participants
Core Phase: Distribution of Reduction From Baseline in Seizure Frequency
Percentage of participantsEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
100% (seizure free)5.13.80.8
≥ 75 to <100 (75% responder)6.015.45.0
≥ 50 to <75 (50% responder)17.120.89.2
≥ 25 to <50 (25% responder)23.930.022.7
>-25 to <25 (No change)35.018.541.2
≤ -25 (Exacerbation)12.811.520.2
Missing (missing)0.00.00.8
SecondaryCore Phase: Changes From Baseline in Number of Seizure-free Days

Comparison of seizure-free days relative to baseline in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during maintenance period of the core phase

Time frame:
Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Reported as:
Median · Number of seizure-free days -per 28 days
Core Phase: Changes From Baseline in Number of Seizure-free Days
Number of seizure-free days -per 28 daysEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Core Phase: Changes From Baseline in Number of Seizure-free Days2.00 (-23.1 to 27.7)4.01 (-10.0 to 27.5)0.47 (-13.4 to 21.8)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Mean difference (final values): 1.4 · 95% CI -0.4 to 3.1
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Mean difference (final values): 4.2 · 95% CI 2.5 to 5.9
SecondaryCore Phase: Probability That a Patient Remains On-treatment up to a Specified Time Point

Comparison of time to treatment discontinuation in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm during the core phase. Treatment duration is defined as the time from randomization until the date of permanent study treatment discontinuation (for any reason) at any time during the Core phase. The percentage event-free probability estimate is the estimated probability that a patient will remain on-treatment up to a specified time point (Week 6, 12, 18)

Time frame:
Week 6, Week 12, Week 18
Reported as:
Number · Percentage event-free prob. estimates
Core Phase: Probability That a Patient Remains On-treatment up to a Specified Time Point
Percentage event-free prob. estimatesEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Week 697.4 (92.3 to 99.2)96.2 (91.0 to 98.4)99.2 (94.2 to 99.9)
Week 1295.7 (90.0 to 98.2)95.4 (90.0 to 97.9)97.5 (92.4 to 99.2)
Week 1870.1 (60.9 to 77.5)71.5 (62.9 to 78.5)75.6 (66.9 to 82.4)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Hazard ratio (hr): 1.27 · 95% CI 0.77 to 2.07
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Hazard ratio (hr): 1.20 · 95% CI 0.74 to 1.96
SecondaryCore Phase: Change From Baseline in the QOLCE Overall Quality-of-life Score for Patients <11 Years

Comparison of quality of life in the everolimus (from 3 age specific questionnaires) low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life Childhood Epilepsy (QOLCE) questionnaire, used for patients \< 11 years at baseline, was completed by the patient's parent or caregiver. It consists of 16 subscales (13 multi-item scales and 3 single item scales) and one overall quality-of-life score. Scores range from 0-100, with higher scores corresponding to improved QoL. The Overall Quality of Life Score is computed by adding each subscale score for each individual and then dividing by 16.

Time frame:
Baseline, Week 18
Reported as:
Median · scores on a scale
Core Phase: Change From Baseline in the QOLCE Overall Quality-of-life Score for Patients <11 Years
scores on a scaleEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Baseline52.3 (26 to 75)56.5 (26 to 76)55.3 (33 to 74)
End of Core Phase53.6 (24 to 79)59.5 (36 to 78)57.2 (20 to 77)
Change from Baseline0.2 (-25 to 24)0.0 (-19 to 18)1.0 (-18 to 28)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Difference in least square means: -1.1 · 95% CI -4.4 to 2.1
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Difference in least square means: 1.0 · 95% CI -2.2 to 4.3
SecondaryCore Phase: Change From Baseline in the QOLIE-AD-48 Overall Quality-of-life Score for Patients >=11 to 18 Years

Comparison of quality of life (from 3 age specific questionnaires) in the everolimus low-trough treatment arm (3-7 ng/mL), hightrough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life in Epilepsy Inventory for Adolescents-48 (QOLIE-AD-48) is a survey of health-related quality of life for adolescents 11 to 18 years of age with epilepsy. The QOLIE-AD-48 is completed by the patient. It contains 48 items which assess 8 subscales. Scores range from 0-100, with higher scores corresponding to improved QoL. The overall quality of life score is obtained by summing a linear combination of the 8 subscale scores, where each subscale is multiplied by a relative weight that is provided in the original publication.

Time frame:
Baseline, Week 18
Reported as:
Median · scores on a scale
Core Phase: Change From Baseline in the QOLIE-AD-48 Overall Quality-of-life Score for Patients >=11 to 18 Years
scores on a scaleEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Baseline56.1 (43 to 86)58.8 (35 to 81)59.6 (13 to 88)
End of Core Phase58.5 (47 to 89)60.7 (46 to 74)65.4 (29 to 87)
Change from Baseline4.7 (-11 to 11)5.8 (-13 to 38)7.2 (-18 to 25)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Difference in least square means: -2.1 · 95% CI -10.5 to 6.2
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Difference in least square means: 0.4 · 95% CI -7.8 to 8.6
SecondaryCore Phase: Change From Baseline in the QOLIE-31-P Overall Quality-of-life Score for Patients Aged >=18 Years

Comparison of quality of life (from 3 age specific questionnaires) in the everolimus low-trough treatment arm (3-7 ng/mL), hightrough treatment arm (9-15 ng/mL) and placebo arm at the end of the core phase. The Quality of Life in Epilepsy Inventory-31-Problems (QOLIE-31-P) is a survey of health-related quality of life for adults with epilepsy. The QOLIE-31-P is completed by the patient. It contains 39 items, of which a total of 30 are used to make up 7 different subscales. Scores range from 0-100, with higher scores indicating a greater level of functioning and QoL. The overall quality of life score is obtained by summing a linear combination of the 7 subscale scores, where each subscale is multiplied by a relative weight that is obtained from the patient's answer to 7 items of this questionnaire.

Time frame:
Baseline, Week 18
Reported as:
Median · scores on a scale
Core Phase: Change From Baseline in the QOLIE-31-P Overall Quality-of-life Score for Patients Aged >=18 Years
scores on a scaleEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Baseline39.5 (13 to 64)43.2 (5 to 89)43.6 (11 to 83)
End of Core Phase48.6 (11 to 54)37.1 (6 to 97)54.8 (26 to 90)
Change from Baseline-0.5 (-17 to 34)0.4 (-47 to 20)5.3 (-16 to 36)
Statistical analysis
  • Everolimus LT Target of 3 to 7 ng/mL vs Placebo · Difference in least square means: -2.8 · 95% CI -17.9 to 12.3
  • Everolimus HT Target of 9 to 15 ng/mL vs Placebo · Difference in least square means: -7.7 · 95% CI -22.0 to 6.6
SecondaryCore Phase: Change From Baseline in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score

Comparison of adaptive functioning using the VABS-II composite score in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Vineland II assesses an individual's development of personal independence \& social responsibility. The questionnaire contains 433 items which assess 15 subdomains organized into the five domains of Communication, Daily Living Skills, Socialization, Motor Skills and Maladaptive Behavior. The overall Adaptive Behavior Composite (ABC) score is obtained by summing the standard scores of the first four domain scores for patients aged less than 7 years, or the first 3 domain scores for patients aged 7 or older (the Maladaptive Behavior domain is optional). The ABC standard score ranges from 20 to 160 with a mean of 100 and a standard deviation of 15. Higher scores correspond to improved adaptive level. Note that 2 questionnaires with ABC scores\<20 (data issues) were included in this analysis.

Time frame:
Baseline, 18 weeks
Reported as:
Median · scores on a scale
Core Phase: Change From Baseline in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score
scores on a scaleEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Baseline58.00 (20.0 to 112.0)56.50 (20.0 to 102.0)55.00 (20.0 to 103.0)
End of Core Phase54.00 (6.0 to 121.0)55.00 (20.0 to 111.0)55.00 (20.0 to 105.0)
Change from Baseline-1.00 (-21.0 to 15.0)0.00 (-13.0 to 15.0)0.00 (-12.0 to 10.0)
SecondaryLong Term Evaluation: Effect of Everolimus Over Time in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score

Comparison of adaptive functioning using the VABS-II composite score in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Vineland II assesses an individual's development of personal independence \& social responsibility. The questionnaire contains 433 items which assess 15 subdomains organized into the five domains of Communication, Daily Living Skills, Socialization, Motor Skills and Maladaptive Behavior. The overall Adaptive Behavior Composite (ABC) score is obtained by summing the standard scores of the first four domain scores for patients aged less than 7 years, or the first 3 domain scores for patients aged 7 or older (the Maladaptive Behavior domain is optional). The ABC standard score ranges from 20 to 160 with a mean of 100 and a standard deviation of 15. Higher scores correspond to improved adaptive level. Note that 2 questionnaires with ABC scores\<20 (data issues) were included in this analysis.

Time frame:
Baseline, Weeks 18, 42, 66 and 90
Reported as:
Median · scores on a scale
Long Term Evaluation: Effect of Everolimus Over Time in the Overall Vineland-II Adaptive Behavior Composite (ABC) Score
scores on a scaleEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboEverolimus Long Term Evaluation (LTE)
Baseline———56.00 (20.0 to 112.0)
Week 18———53.50 (4.0 to 121.0)
Week 42———55.50 (20.0 to 111.0)
Week 66———57.00 (20.0 to 112.0)
Week 90———49.50 (20.0 to 150.0)
SecondaryCore Phase: Change From Baseline in Wechsler Nonverbal Composite Score

The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range.

Time frame:
Baseline, Week 18
Reported as:
Median · scores on a scale
Core Phase: Change From Baseline in Wechsler Nonverbal Composite Score
scores on a scaleEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboEverolimus Long Term Evaluation (LTE)
Baseline-0.48 (-2.3 to 8.1)-0.69 (-2.3 to 9.6)-1.11 (-2.3 to 8.3)—
End of Core Phase-0.04 (-2.3 to 8.1)-0.89 (-2.3 to 7.5)-0.51 (-2.3 to 10.1)—
Change from Baseline0.00 (-2.5 to 1.6)0.00 (-10.0 to 2.1)0.00 (-3.3 to 1.7)—
SecondaryLong Term Evaluation: Effect of Everolimus Over Time in the Overall Wechsler Nonverbal Composite Score

The brief version of the WNV consists of a 2-subtest battery: only Matrices and Recognition subtests for patients under 8, and Matrices and Spatial Span subtests for patients aged 8 to 21. Based on the raw scores obtained from the subtests, standardized z-scores were calculated for each subtest using the following formula: Zscore = (X - b)/Sb where X is the raw score of the subtest, b and Sb represent the mean and standard deviation respectively of the subtest score recorded at baseline for the study population. The composite WNV score was computed by summing up the Z-scores of the 3 subtests of the WNV (i.e. matrices, recognition, and coding for patients aged \<8 years and matrices, spatial span, and coding for patients aged 8 to 21 years). The composite WNV score has no range

Time frame:
Baseline, Weeks 18, 42, 66 and 90
Reported as:
Median · scores on a scale
Long Term Evaluation: Effect of Everolimus Over Time in the Overall Wechsler Nonverbal Composite Score
scores on a scaleEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboEverolimus Long Term Evaluation (LTE)
Baseline———-0.53 (-2.3 to 10.1)
Week 18———-0.44 (-2.3 to 9.5)
Week 42———-0.36 (-2.3 to 10.8)
Week 66———0.13 (-2.3 to 9.1)
Week 90———-0.06 (-2.3 to 9.0)
SecondaryCore Phase: Response Rate in Seizure Frequency by Time Normalized Minimum Concentration

Comparison of response rate in seizure frequency for 5 categories of time-normalized minimum concentration (Cmin, TN) (\< 3 ng/mL; 3-7 ng/mL; \>7-\<9 ng/mL; 9-15 ng/mL; \>15 ng/mL). Response rate is the percentage of patients with ≥ 50% reduction from baseline in average weekly partial-onset seizure frequency during the maintenance period of the Core phase.

Time frame:
Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Reported as:
Median · Percentage of responders
Core Phase: Response Rate in Seizure Frequency by Time Normalized Minimum Concentration
Percentage of responders<3 ng/mL3-7 ng/mL>7-<9 ng/mL9-15 ng/mL>15 ng/mL
Core Phase: Response Rate in Seizure Frequency by Time Normalized Minimum Concentration14.3 (1.8 to 42.8)29.9 (22.7 to 38.0)44.2 (30.5 to 58.7)50.0 (31.3 to 68.7)50.0 (1.3 to 98.7)
SecondaryCore Phase: Median Percentage Change From Baseline in Seizure Frequency by Time Normalized Minimum Concentration

Percentage change from baseline in average weekly seizure frequency during the maintenance period of the Core phase is calculated as follow: (SFcfb) = 100 × (SFB - SFM) ÷ SFB where SFB is the average weekly seizure frequency in the Baseline phase and SFM is the average weekly seizure frequency in the maintenance period of the Core phase. A positive percentage change from baseline (SFcfb) means a reduction in seizure frequency whereas a negative percentage change from baseline (SFcfb) means an increase in seizure frequency.

Time frame:
Baseline (8-week period before randomization), Week 7 to 18 (12-week maintenance period of the core phase)
Reported as:
Median · Percentage change
Core Phase: Median Percentage Change From Baseline in Seizure Frequency by Time Normalized Minimum Concentration
Percentage change<3 ng/mL3-7 ng/mL>7-<9 ng/mL9-15 ng/mL>15 ng/mL
Core Phase: Median Percentage Change From Baseline in Seizure Frequency by Time Normalized Minimum Concentration20.55 (-8.45 to 35.39)35.56 (24.43 to 41.88)39.72 (28.02 to 62.79)47.69 (36.46 to 66.32)61.56 (42.73 to 80.38)
SecondaryLong Term Evaluation: Relationship Between Seizure Frequency and Time-normalized Everolimus Concentration at Trough (Cmin,TN) - Repeated Measures Analysis

A repeated measures analysis considering fixed 2-week intervals and including the level of exposure (time-normalized Cmin values), the time on-treatment and the seizure frequency at baseline quantified the estimated percentage change over 2 weeks in seizure frequency associated with a double exposure to everolimus, 15 days more on treatment and half the seizure frequency at baseline. A positive percentage change means a reduction in seizure frequency whereas a negative percentage change means an increase in seizure frequency.

Time frame:
During everolimus treatment from start of everolimus up to the end of the extension phase, an average of 1.7 year
Reported as:
Mean · % change over 2-wk in seizures freq.
Long Term Evaluation: Relationship Between Seizure Frequency and Time-normalized Everolimus Concentration at Trough (Cmin,TN) - Repeated Measures Analysis
% change over 2-wk in seizures freq.Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboEverolimus Long Term Evaluation (LTE)
By doubling the time-normalized Cmin (log scale)———8.93 (6.87 to 10.95)
By reporting half the seizure freq. at baseline———48.82 (46.37 to 51.15)
By adding 12 weeks on treatmen———6.42 (4.53 to 8.27)
SecondaryCore Phase: Impact of Everolimus on Anti-epileptic Drugs (AEDs) Concentrations

Impact of everolimus on AED concentrations at trough. Pre-dose plasma samples to measure AED concentrations were measured at at Visits 1 (Screening), 2 (Baseline), 3, and 5. Effects of everolimus on the exposure of antiepileptic drugs was assessed by comparing the anti-epileptic drug concentrations at Visits 1 and 2 (AEDs alone) and at Visits 3 and 5 (AEDs plus everolimus).

Time frame:
Baseline, Weeks 1 & 3
Reported as:
Geometric mean · ng/mL
Core Phase: Impact of Everolimus on Anti-epileptic Drugs (AEDs) Concentrations
ng/mLValporic AcidCarbamazepineClobazamN-desmethylclobazamTopiramateTRI477TRI476ClonazepamZonisamidePhenobarbitalPhenytoin
Core Phase: Impact of Everolimus on Anti-epileptic Drugs (AEDs) Concentrations0.962 (0.913 to 1.014)1.108 (1.016 to 1.208)1.093 (1.037 to 1.153)1.071 (1.017 to 1.127)0.983 (0.872 to 1.108)1.086 (0.913 to 1.291)1.194 (0.936 to 1.523)1.065 (0.974 to 1.163)1.028 (0.971 to 1.089)0.957 (0.886 to 1.034)1.020 (0.874 to 1.190)
SecondaryLong Term Evaluation: Percentage Change From Start of Everolimus in Seizure Frequency by Time Window

Percentage change from start of everolimus in average weekly seizure frequency (SFcfe) = 100 × (SFe - SFtw) ÷ SFe where: SFe is the average weekly seizure frequency in the 8-week period before start of everolimus SFtw is the average weekly seizure frequency in a 12-week time window A positive percentage change from start of everolimus (SFcfe) means a reduction in seizure frequency whereas a negative percentage change from start of everolimus (SFcfe) means an increase in seizure frequency.

Time frame:
Baseline (8-week period before start of everolimus), Week 7 to 18, Week 19 to 30, and 12 weeks thereafter up to Week 102
Reported as:
Median · Percent change
Long Term Evaluation: Percentage Change From Start of Everolimus in Seizure Frequency by Time Window
Percent changeEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboEverolimus Long Term Evaluation (LTE)
Week 18———31.65 (28.51 to 36.09)
Week 30———35.74 (29.37 to 39.06)
Week 42———42.86 (34.44 to 48.15)
Week 54———46.05 (39.93 to 53.61)
Week 66———49.07 (38.26 to 55.56)
Week 78———51.69 (43.88 to 61.58)
Week 90———57.33 (47.37 to 67.01)
Week 102———59.69 (52.13 to 70.94)
SecondarySeizure Free Rates by Time Window

Percentage of seizure-free participants for each 12-week time window.

Time frame:
Weeks 18, 30, 42, 54, 66, 78, 90 & 102
Reported as:
Number · Percentage of seizure-free participants
Seizure Free Rates by Time Window
Percentage of seizure-free participantsEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboEverolimus Long Term Evaluation (LTE)
Week 18———3.98 (2.2 to 6.6)
Week 30———6.87 (4.4 to 10.1)
Week 42———8.44 (5.6 to 12.0)
Week 54———8.70 (5.8 to 12.5)
Week 66———10.99 (7.6 to 15.2)
Week 78———13.49 (9.5 to 18.3)
Week 90———14.86 (10.5 to 20.2)
Week 102———15.18 (10.4 to 21.1)
SecondaryCore Phase: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes

Comparison of suicidality using the C-SSRS in the everolimus low-trough treatment arm (3-7 ng/mL), high-trough treatment arm (9-15 ng/mL) and placebo arm. The Columbia-Suicide Severity Rating Scale (C-SSRS) is a questionnaire used for suicide assessment developed by multiple institutions, including Columbia University, with NIMH support. The scale is evidence-supported and is part of a national and international public health initiative involving the assessment of suicidality. There are different scoring systems depending on the population. The important elements to note are that the higher the scores on the individual items and the more "yes" items, the higher the suicide risk.

Time frame:
Baseline, Week 18
Reported as:
Number · Participants
Core Phase: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes
ParticipantsEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlacebo
Completed suicide000
Suicide attempt100
Prep actions toward imminent suicidal behavior200
Suicidal ideation310
Self-injurious behavior without suicide intent000
SecondaryLong Term Evaluation: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes

The C-SSRS was completed at each visit. The table below presents the number of patients who reported at least one completed suicide, one suicide attempt, one preparatory action toward imminent suicidal behavior, one suicidal ideation and one self-injurious behavior without suicidal intent at any time point after starting everolimus.

Time frame:
During everolimus treatment from start of everolimus up to permanent discontinuation of everolimus, an average of 2.3 years
Reported as:
Number · Participants
Long Term Evaluation: Incidence of Suicide Attempt, Suicidal Ideation or Behavior During Core Phase Per Columbia Suicide Severity Rating Scale (C-SSRS) Outcomes
ParticipantsEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboEverolimus Long Term Evaluation (LTE)
Completed suicide———0
Suicidal attempt———1
Prep. actions toward imminent suicidal behavior———2
Suicidal ideation———7
Self-injurious behavior without suicide intent———1

Adverse events

Collected over Adverse Events were collected during everolimus treatment from start of everolimus up to permanent discontinuation of everolimus, an average of 2.3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus LT Target of 3 to 7 ng/mL1/117 (0.9%)50/117 (42.7%)110/117 (94%)
Everolimus HT Target of 9 to 15 ng/mL2/130 (1.5%)49/130 (37.7%)126/130 (96.9%)
Everolimus Start Ext1/114 (0.9%)38/114 (33.3%)109/114 (95.6%)
Everolimus All4/361 (1.1%)137/361 (38%)345/361 (95.6%)
Most frequent serious events
Showing 10 of 144
Most frequent serious events
EventEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLEverolimus Start ExtEverolimus All
PneumoniaInfections and infestations16/11713/1309/11438/361
SeizureNervous system disorders7/1177/1304/11418/361
Status epilepticusNervous system disorders7/1176/1302/11415/361
PyrexiaGeneral disorders5/1174/1302/11411/361
GastroenteritisInfections and infestations5/1175/1304/11414/361
TonsillitisInfections and infestations0/1172/1303/1145/361
Viral infectionInfections and infestations0/1170/1303/1143/361
DiarrhoeaGastrointestinal disorders3/1172/1300/1145/361
Mouth ulcerationGastrointestinal disorders3/1170/1301/1144/361
InfluenzaInfections and infestations3/1171/1302/1146/361
Most frequent other events
Showing 10 of 61
Most frequent other events
EventEverolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLEverolimus Start ExtEverolimus All
PyrexiaGeneral disorders47/11756/13031/114134/361
DiarrhoeaGastrointestinal disorders45/11742/13030/114117/361
StomatitisGastrointestinal disorders41/11748/13041/114130/361
Mouth ulcerationGastrointestinal disorders36/11744/13022/114102/361
Upper respiratory tract infectionInfections and infestations32/11742/13022/11496/361
NasopharyngitisInfections and infestations33/11735/13026/11494/361
VomitingGastrointestinal disorders28/11735/13016/11479/361
CoughRespiratory, thoracic and mediastinal disorders29/11733/13015/11477/361
Aphthous ulcerGastrointestinal disorders11/11723/13010/11444/361
HeadacheNervous system disorders19/11719/13010/11448/361

Baseline characteristics

Full Analysis Set: The Full Analysis Set (FAS) comprised all patients to whom study treatment was assigned by randomization.

Age, Continuous
Age, Continuous(years)Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboTotal
Median9.72 (2.2 to 56.3)10.08 (2.3 to 50.5)10.34 (2.2 to 52.0)10.06 (2.2 to 56.3)
Age, Customized
Age, Customized(Participants)Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboTotal
< 6 years333734104
6 to <12 years373937113
12 to <18 years26312582
18 to <65 years21232367
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboTotal
Female536558176
Male646561190
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboTotal
Caucasian768477237
Asian29312787
Black2114
Native American0101
Pacific Islander1001
Other9131436
Weight
Weight(kg)Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboTotal
Mean38.69 ± 22.80240.75 ± 27.26740.50 ± 24.92340.01 ± 25.093
Height
Height(cm)Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboTotal
Mean135.65 ± 26.171136.25 ± 28.234135.67 ± 27.097135.87 ± 27.145
Body surface area
Body surface area(m^2)Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboTotal
Mean1.18 ± 0.4371.20 ± 0.5011.20 ± 0.4761.20 ± 0.472
Body mass index
Body mass index(kg/m^2)Everolimus LT Target of 3 to 7 ng/mLEverolimus HT Target of 9 to 15 ng/mLPlaceboTotal
Mean19.29 ± 5.28319.56 ± 6.23319.78 ± 5.48419.55 ± 5.689
08

Study locations

104 sites
  • University of Alabama at Birmingham SC
    Birmingham, Alabama 35294, United States
  • TGen/APNNA
    Phoenix, Arizona 85012, United States
  • University of California at Los Angeles SC
    Los Angeles, California 90095, United States
  • Children's Hospital Oakland SC
    Oakland, California 94609, United States
  • Children's Hospital of Orange County SC
    Orange, California 92868-3874, United States
  • Rady Children's Hospital SC
    San Diego, California 92123, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Connecticut Childrens Medical Center SC
    Hartford, Connecticut 06106, United States
  • University of Chicago SC - 2
    Chicago, Illinois 60637, United States
  • Kennedy Krieger Institute SC
    Baltimore, Maryland 21205, United States
  • Children's Hospital Boston SC
    Boston, Massachusetts 02115, United States
  • Minnesota Epilepsy Group - PA SC
    Saint Paul, Minnesota 55102-2383, United States
  • Washington University School of Medicine SC-2
    Saint Louis, Missouri 63110, United States
  • Morristown Memorial Hospital SC-2
    Morristown, New Jersey 07962, United States
  • New York University Medical Center SC-3
    New York, New York 10016, United States
  • Cincinnati Children's Hospital Medical Center SC
    Cincinnati, Ohio 45229-3039, United States
  • Oregon Health and Science University SC - 3
    Portland, Oregon 97239, United States
  • Children's Hospital of Philadelphia SC
    Philadelphia, Pennsylvania 19104-4399, United States
  • LeBonheur Childrens Medical Group SC
    Memphis, Tennessee 38103, United States
  • Texas Scottish Rite Hospital for Children Texas Scottish
    Dallas, Texas 75219, United States
  • Texas Children s Hospital SC
    Houston, Texas 77030, United States
  • The University of Texas Medical School-Houston SC
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1428AQK, Argentina
  • Novartis Investigative Site
    Cordoba, X5000JJS, Argentina
  • Novartis Investigative Site
    Randwick, New South Wales 2031, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3052, Australia
  • Novartis Investigative Site
    Perth, Western Australia 6840, Australia
  • Novartis Investigative Site
    Jette, Brussel 1090, Belgium
  • Novartis Investigative Site
    Bruxelles, 1070, Belgium
  • Novartis Investigative Site
    Bruxelles, 1200, Belgium
  • Novartis Investigative Site
    Gent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Vancouver, British Columbia V6H 3V4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H3T 1C5, Canada
  • Novartis Investigative Site
    Cali, Valle Del Cauca, Colombia
  • Novartis Investigative Site
    Bogotá, Colombia
  • Novartis Investigative Site
    Medellín, Colombia
  • Novartis Investigative Site
    Aarhus, 8000 C, Denmark
  • Novartis Investigative Site
    Amiens Cedex 1, 80054, France
  • Novartis Investigative Site
    Angers cedex 09, 49933, France
  • Novartis Investigative Site
    Bron Cedex, 69677, France
  • Novartis Investigative Site
    Lille Cedex, 59037, France
  • Novartis Investigative Site
    Marseille, 13385, France
  • Novartis Investigative Site
    Strasbourg Cedex, F-67098, France
  • Novartis Investigative Site
    Berlin, 12351, Germany
  • Novartis Investigative Site
    Bielefeld, 33617, Germany
  • Novartis Investigative Site
    Kehl-Kork, 77694, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Ioannina, GR 455 00, Greece
  • Novartis Investigative Site
    Athens, 15236, Greece
  • Novartis Investigative Site
    Budapest, 1145, Hungary
  • Novartis Investigative Site
    Kaposvar, 7400, Hungary
  • Novartis Investigative Site
    Nyiregyhaza, 4400, Hungary
  • Novartis Investigative Site
    Dublin, 12, Ireland
  • Novartis Investigative Site
    Bari, BA 70124, Italy
  • Novartis Investigative Site
    Bologna, BO 40133, Italy
  • Novartis Investigative Site
    Catania, CT 95100, Italy
  • Novartis Investigative Site
    Genova, GE 16147, Italy
  • Novartis Investigative Site
    Milano, MI 20142, Italy
  • Novartis Investigative Site
    Pavia, PV 27100, Italy
  • Novartis Investigative Site
    Roma, RM 00161, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Okayama-city, Okayama 700-8558, Japan
  • Novartis Investigative Site
    Izumi-city, Osaka 594-1101, Japan
  • Novartis Investigative Site
    Suita-city, Osaka 565 0871, Japan
  • Novartis Investigative Site
    Shizuoka-city, Shizuoka 420-8688, Japan
  • Novartis Investigative Site
    Setagaya-ku, Tokyo 157-8535, Japan
  • Novartis Investigative Site
    Osaka, 534-0021, Japan
  • Novartis Investigative Site
    Seoul, Korea 03080, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, Korea 06351, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 03722, Korea, Republic of
  • Novartis Investigative Site
    Guadalajara, Jalisco 44280, Mexico
  • Novartis Investigative Site
    Heeze, 5591 VE, Netherlands
  • Novartis Investigative Site
    Rotterdam, 3015 CN, Netherlands
  • Novartis Investigative Site
    Utrecht, 3584CX, Netherlands
  • Novartis Investigative Site
    Oslo, 0424, Norway
  • Novartis Investigative Site
    Warszawa, 04 730, Poland
  • Novartis Investigative Site
    Samara, Samara Region 443095, Russian Federation
  • Novartis Investigative Site
    Voronezh, Voronezh Region 394024, Russian Federation
  • Novartis Investigative Site
    Moscow, 119991, Russian Federation
  • Novartis Investigative Site
    Moscow, 127412, Russian Federation
  • Novartis Investigative Site
    Sevilla, Andalucía 41013, Spain
  • Novartis Investigative Site
    Barcelona, Catalunya 08035, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46026, Spain
  • Novartis Investigative Site
    San Sebastian, Pais Vasco 20080, Spain
  • Novartis Investigative Site
    Madrid, 28009, Spain
  • Novartis Investigative Site
    Tainan, Taiwan ROC 70421, Taiwan
  • Novartis Investigative Site
    Kaohsiung City, 83301, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10400, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Ankara, 06100, Turkey
  • Novartis Investigative Site
    Ankara, 06500, Turkey
  • Novartis Investigative Site
    Istanbul, 34093, Turkey
  • Novartis Investigative Site
    Birmingham, B15 2WB, United Kingdom
  • Novartis Investigative Site
    Buckinghamshire, SL9 0RJ, United Kingdom
  • Novartis Investigative Site
    Cambridge, CB2 2QQ, United Kingdom
  • Novartis Investigative Site
    Liverpool, L12 2AP, United Kingdom

Showing the first 100 of 104 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Curatolo P, Franz DN, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, de Vries PJ, Dlugos DJ, Fan J, Ridolfi A, Pelov D, Voi M, French JA. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. Lancet Child Adolesc Health. 2018 Jul;2(7):495-504. doi: 10.1016/S2352-4642(18)30099-3. Epub 2018 May 24. PubMed 30169322 ↗
  • French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016 Oct 29;388(10056):2153-2163. doi: 10.1016/S0140-6736(16)31419-2. Epub 2016 Sep 6. PubMed 27613521 ↗
  • Goyer I, Dahdah N, Major P. Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex. Pediatr Neurol. 2015 Apr;52(4):450-3. doi: 10.1016/j.pediatrneurol.2015.01.004. Epub 2015 Jan 14. PubMed 25682485 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Oct 2017, 53 months.

Results were first posted in Nov 2018, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Seizures, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 79. This study's 53 months is close to that.

Counting every sponsor, half of 51 studies reached it within 54 months; a quarter within 33 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2012
First posted
Oct 25, 2012
StartActual
Apr 29, 2013
Primary completionActual
Oct 25, 2017
CompletionActual
Oct 25, 2017
Results first posted
Nov 7, 2018
Last update
Nov 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01713946
Responsible party
Sponsor
First posted
Oct 25, 2012
Start date
Apr 29, 2013
Primary completion
Oct 25, 2017
Completion
Oct 25, 2017
Results posted
Nov 7, 2018
Last update
Nov 7, 2018

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion